This week, AliveCor's patent infringement lawsuit against Apple came to an end; industry stakeholders submitted comments to the FTC on the right to repair; Cardinal Health and Percussionaire announced recalls; and the IMDRF announced a March meeting in Washington, DC.

Oncology-focused Innovo, CytosinLab, Sino-Cell and Sinogen announced closings of early-stage funding rounds worth up to $14m. Meanwhile, Chinese developers of therapies for asthma, autoimmune skin disorders and rare diseases also raised similar new funds.

Six Chinese biotechs raise a combined $141m in major financing deals backed by venture capital and private equity firms.

At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.